caa a22 4500 445333545 CHVBK 20180317142745.0 cr unu---uuuuu 170323e20110601xx s 000 0 eng 10.1245/s10434-010-1528-8 doi (NATIONALLICENCE)springer-10.1245/s10434-010-1528-8 Ratio of Metastatic To Resected Lymph Nodes Enhances To Predict Survival In Patients With Stage III Colorectal Cancer [Elektronische Daten] [Hai-Bo Qiu, Li-Yi Zhang, Yuan-Fang Li, Zhi-Wei Zhou, Rajiv Keshari, Rui-Hua Xu] Background: The objective of this study was to assess the value of metastatic lymph node ratio in predicting prognosis of patients with stage III colorectal cancer. Methods: From 2000 to 2005 inclusively, a total of 626 patients featuring stage III colorectal cancer underwent curative resection. These patients were stratified into LNR groups: 1 (0<LNR≤0.1); 2 (0.1<LNR≤0.25); 3 (0.25<LNR≤0.5); and 4 (LNR>0.5). The follow-up was closed in April 2010. Kaplan-Meier survival curve and log-rank test were used to evaluate the prognostic value of LNR. A Cox regression model was used for multivariate analyses. Results: With a median follow-up period of 42.2months, 5-year overall survival for groups LNR1, LNR2, LNR3, and LNR4 was 73%, 64%, 44%, and 22%, respectively. In the multivariate analysis, the LNR was an independent prognostic factor for survival (P<0.001). LNR remained statistically significant (P<0.001), both in patients with colon and rectum cancer regardless of the number of lymph nodes retrieved (≥12 or<12). The survival rate of ratio group LNR1 was better than ratio group LNR4 (P<0.001) for patients with the same IIIB or IIIC staging. Conclusions: LNR is an accurate prognostic method for patients with stage III colorectal cancer. We proposed an algorithm to incorporate LNR into current AJCC staging system to form new staging. Society of Surgical Oncology, 2011 Qiu Hai-Bo State Key Laboratory of Oncology in South China, Guangzhou, Guangdong, China aut Zhang Li-Yi Department of Clinical Oncology, The University of Hong Kong, Hong Kong, China aut Li Yuan-Fang State Key Laboratory of Oncology in South China, Guangzhou, Guangdong, China aut Zhou Zhi-Wei State Key Laboratory of Oncology in South China, Guangzhou, Guangdong, China aut Keshari Rajiv State Key Laboratory of Oncology in South China, Guangzhou, Guangdong, China aut Xu Rui-Hua State Key Laboratory of Oncology in South China, Guangzhou, Guangdong, China aut Annals of Surgical Oncology Springer-Verlag 18/6(2011-06-01), 1568-1574 1068-9265 18:6<1568 2011 18 10434 https://doi.org/10.1245/s10434-010-1528-8 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1245/s10434-010-1528-8 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Qiu Hai-Bo State Key Laboratory of Oncology in South China, Guangzhou, Guangdong, China aut NATIONALLICENCE 700 1- Zhang Li-Yi Department of Clinical Oncology, The University of Hong Kong, Hong Kong, China aut NATIONALLICENCE 700 1- Li Yuan-Fang State Key Laboratory of Oncology in South China, Guangzhou, Guangdong, China aut NATIONALLICENCE 700 1- Zhou Zhi-Wei State Key Laboratory of Oncology in South China, Guangzhou, Guangdong, China aut NATIONALLICENCE 700 1- Keshari Rajiv State Key Laboratory of Oncology in South China, Guangzhou, Guangdong, China aut NATIONALLICENCE 700 1- Xu Rui-Hua State Key Laboratory of Oncology in South China, Guangzhou, Guangdong, China aut NATIONALLICENCE 773 0- Annals of Surgical Oncology Springer-Verlag 18/6(2011-06-01), 1568-1574 1068-9265 18:6<1568 2011 18 10434 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer